Prime Medicine financials
$3.09+7.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $4.6M | $3.0M | $0.00 | $0.00 |
| Gross profit | $4.6M | $3.0M | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | — | — |
| Operating income | -$208.3M | -$202.5M | -$204.8M | -$116.5M |
| Net income | -$201.1M | -$195.9M | -$198.1M | -$142.0M |
| Net margin | −4342.4% | −6566.6% | — | — |
| Diluted EPS | $-1.35 | $-1.65 | $-2.18 | $-4.19 |
| EBITDA | -$201.0M | -$196.3M | -$200.1M | -$104.5M |
| Operating cash flow | -$162.6M | -$122.9M | -$165.4M | -$131.8M |
| Free cash flow | -$167.1M | -$130.2M | -$174.1M | -$147.9M |
| Diluted shares | 148.8M | 118.6M | 91.0M | 33.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $63.0M | $182.5M | $41.6M | $187.6M |
| Short-term investments | $114.6M | $8.0M | $80.1M | $98.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $342.7M | $297.5M | $193.9M | $360.3M |
| Total liabilities | $221.9M | $144.4M | $60.8M | $44.0M |
| Shareholders' equity | $120.9M | $153.1M | $133.1M | $316.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology